Clinical Trial

Lassa Fever Clinical Course and Prognostic Factors in Nigeria

Study acronym: LASCOPE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The investigators propose to conduct a nationwide (Nigeria), prospective, non-interventional cohort study describing the clinical course, biological characteristics, case management and outcomes in patients hospitalized for a suspected or confirmed diagnosis of Lassa fever in tertiary medical facilities situated in the most affected Nigerian states. Special focuses will be made on situations at risk of bad outcome such as pregnancies, acute kidney injury and electrolytic imbalance in patients with confirmed Lassa fever. Participants for which the diagnosis of Lassa fever will be finally excluded by reverse-transcriptase polymerase chain reaction (RT-PCR) will constitute the control group.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-08-30; most recent amendment 2025-01-27.
Status change: Recruiting → Active, Not Recruiting 2025-01-27
Trial Details
NCT Number NCT03655561
Lead Sponsor Alliance for International Medical Action
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France, University of Oxford, Irrua Specialist Teaching Hospital, Bernhard Nocht Institute for Tropical Medicine, University Hospital, Bordeaux, University of Bordeaux, PACCI Program, Institut de Recherche pour le Developpement, ANRS, Emerging Infectious Diseases, Federal Medical Centre, Owo, European and Developing Countries Clinical Trials Partnership (EDCTP)
Conditions Lassa Fever, Lassa Virus Infection, Pregnancy Complications, Acute Kidney Injury, Acute Kidney Failure, Coma
Enrollment 1,200 participants
Start Date 2018-04-05
Primary Completion 2023-04-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-29